Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» JNJ
JNJ
Orphan drug market to reach $270B by 2028, led by J&J, Vertex and Roche
Fierce Pharma
Wed, 04/24/24 - 08:50 am
orphan drugs
Evaluate Pharma
JNJ
Vertex Pharmaceuticals
Roche
Inside J&J’s strategy to de-gender clinical trials
Pharma Voice
Tue, 04/23/24 - 10:33 am
clinical trials
LGBTQ+
clinical trial diversity
JNJ
AbbVie tops doctor ranking of immunology companies, handily beating Pfizer and J&J
BioSpace
Mon, 04/22/24 - 11:45 am
physicians
AbbVie
JNJ
Pfizer
immunology
‘We think in decades’: J&J’s $30B spending spree may not be over
Medtech Dive
Tue, 04/16/24 - 10:07 pm
JNJ
Medtech
M&A
Abiomed
Laminar
Shockwave Medical
J&J narrowly misses Q1 revenue on lower-than-expected Stelara sales
BioSpace
Tue, 04/16/24 - 11:19 am
JNJ
earnings
Q&A: Legend Biotech CEO on whether Carvykti can meet expectations
Medical Marketing and Media
Mon, 04/15/24 - 11:16 am
Legend Biotech
Carvykti
mutliple myeloma
JNJ
J&J, Rallybio partner on drug development for rare fetal condition
BioPharma Dive
Wed, 04/10/24 - 06:01 pm
JNJ
Rallybio
FNAIT
drug development
7 Billion-Dollar Oncology M&As from Q1
BioSpace
Wed, 04/10/24 - 11:24 am
oncology
M&A
AbbVie
Immunogen
Bristol Myers Squibb
Mirati Therapeutics
RayzeBio
Novartis
MorphoSys
AstraZeneca
Fusion Pharmaceuticals
JNJ
Ambrx
Gracell
J&J scoops up cardio medtech Shockwave Medical for $13.1B
Medical Marketing and Media
Fri, 04/5/24 - 11:54 am
JNJ
M&A
Medtech
Shockwave Medical
Cardiovascular
intravascular lithotripsy
Fierce Biotech's Quarterly IPO and M&A Roundup: Q1'24
Fierce Biotech
Wed, 04/3/24 - 11:36 am
biotech
M&A
IPOs
CG Oncology
Kyverna Therapeutics
Contineum Therapeutics
Boundless Bio
CymaBay Therapeutics
Gilead Sciences
MorphoSys
Novartis
Fusion Pharmaceuticals
AstraZeneca
Ambryx
JNJ
Inhibrix
Aventis
J&J targets rare maternal-fetal diseases: 'We're going for this. No one else has.'
Fierce Biotech
Tue, 04/2/24 - 11:49 am
JNJ
rare disease
maternal-fetal diseases
FNAIT
nipocalimab
Teva, Viatris win new chance to challenge J&J schizophrenia drug patent
Reuters
Mon, 04/1/24 - 12:04 pm
Teva Pharmaceutical
JNJ
Viatris
schizophrenia
patents
Invega Sustenna
J&J can contest evidence linking its talc to cancer, US judge rules
Reuters
Thu, 03/28/24 - 11:14 am
JNJ
legal
talc
ovarian cancer
J&J Wins FDA Nod for Pulmonary Arterial Hypertension Combo Pill
BioSpace
Mon, 03/25/24 - 11:24 am
JNJ
FDA
PAH
Opsynvi
macitentan
tadalafil
J&J's Abiomed sees serious Impella recall linked to heart perforations, 49 deaths
Fierce Biotech
Fri, 03/22/24 - 10:54 am
JNJ
Abiomed
Medtech
Impella
patient deaths
device recalls
Idorsia's Tryvio crosses FDA finish line, offering new mechanism to treat hypertension
Fierce Pharma
Wed, 03/20/24 - 09:49 pm
JNJ
Idorsia
Tryvio
hypertension
FDA
J&J alleges ex-staffer downloaded thousands of files in move to Pfizer
Seeking Alpha
Wed, 03/20/24 - 11:48 am
JNJ
Pfizer
legal
trade secrets
Despite early death concerns, FDA advisers back J&J and Legend's Carvykti and BMS' Abecma for earlier myeloma
Fierce Pharma
Sun, 03/17/24 - 09:30 pm
JNJ
Legend Biotech
CAR-T
FDA
Carvykti
Abecma
Asgard Gets $32M Series A Backing from J&J, Novo and Boehringer
BioSpace
Sun, 03/17/24 - 09:25 pm
Asgard Therapeutics
JNJ
Novo Nordisk
Boehringer Ingelheim
funding
immuno-oncology
BMS’s Breyanzi Becomes First CAR-T Therapy for Two Types of Leukemia
BioSpace
Fri, 03/15/24 - 11:32 am
Bristol Myers Squibb
CAR-T
CLL
Breyanzi
FDA
JNJ
Carvykti
Pages
1
2
3
4
5
6
7
8
9
…
next ›
last »